Beta Bionics Q2 sales beat estimates on pharmacy channel growth

Overview

• Diabetes device maker's Q2 net sales rose 38% yr/yr, beating analyst expectations

• Q2 adjusted EBITDA loss widened yr/yr but was narrower than analyst expectations

• Company improved gross margin to 59% and maintained full-year revenue guidance

Outlook

• Company sees 2026 revenue of $131 mln to $136 mln, unchanged from prior guidance

• Company raises 2026 gross margin outlook to 58.5%-59.5% from 57.5%-59.5%

• Beta Bionics expects to fully commercialize Mint patch pump by end of Q2 2027, pending FDA clearance

Result Drivers

• PBP CHANNEL GROWTH - Co said PBP channel net sales rose 153% yr/yr, contributing to overall revenue growth

• NEW PATIENT STARTS - Co reported new patient starts increased by at least 10% but less than 20% sequentially vs Q1 2026, with 69% coming from multiple daily injections

• GROSS MARGIN IMPROVEMENT - Co reported gross margin of 59.0%, up 524 basis points yr/yr

Company press release: ID:nGNX1wM14j

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment technology peer group is "buy"

• Wall Street's median 12-month price target for Beta Bionics Inc is $20.00, about 26.6% above its July 28 closing price of $15.80

Reuters Recommended Reads

• July 29 - Anika Therapeutics Q2 revenue rises, lifts 2026 outlook

• July 29 - Integra LifeSciences Q2 revenue slightly beats, adjusted EPS tops estimates

• July 28 - Repligen Q2 revenue beats estimates on higher orders; raises outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)